Mohammadpour Mehrdad, Masoumi Ahmad, Mirghorbani Masoud, Shahraki Kianoosh, Hashemi Hassan
Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Noor Research Center for Ophthalmic Epidemiology, Noor Eye Hospital, Tehran, Iran.
J Curr Ophthalmol. 2017 Sep 12;29(4):235-247. doi: 10.1016/j.joco.2017.07.003. eCollection 2017 Dec.
To review the historical background and basic principles of collagen cross-linking, to bring together the data regarding the outcomes and complications of collagen cross-linking and finally to explore the efficacy and safety of new variations of this technique.
A literature review was performed using PubMed and Scopus. The following keywords were used for literature search: cross linking, crosslinking, cross-linking, keratoconus, keratectasia.
In contrast to traditional treatment modalities for keratoconus (KCN), this new technique addresses the progression of the disease. Several clinical studies have been conducted to assess the efficacy of corneal collagen cross-linking (CXL) in the last decade. The results were promising as collagen cross-linking showed significant improvement in visual acuity and keratometric values. Moreover, initial results show that it is a safe procedure with few reported complications.
CXL is an emerging treatment method in ophthalmology that offers the possibility to effectively treat progressive KCN.
回顾胶原交联的历史背景和基本原理，汇总有关胶原交联的结果和并发症的数据，并最终探讨该技术新变体的疗效和安全性。
使用PubMed和Scopus进行文献综述。以下关键词用于文献检索：交联、角膜交联、圆锥角膜、角膜扩张。
与传统的圆锥角膜（KCN）治疗方式不同，这项新技术可解决疾病的进展问题。在过去十年中，已经进行了多项临床研究来评估角膜胶原交联（CXL）的疗效。结果很有前景，因为胶原交联在视力和角膜曲率值方面有显著改善。此外，初步结果表明这是一种安全的手术，报告的并发症很少。
CXL是眼科中一种新兴的治疗方法，为有效治疗进行性KCN提供了可能性。
